You are here

Retail Clinics to Surpass 2,800 in Next Two Years

But most doctors worry about use of clinics for chronic illness, primary care

Retail health clinics will continue to expand throughout the country and will increase by nearly 50 percent in the next two years, according to a new report FiefrceHealthcare.

Accenture, a global professional services company, estimates that by the end of this year, there will be 2,150 walk-in clinics in pharmacies, retail chains, and supermarkets. But that number will top 2,800, reaching capacity for 9 million more patients, by 2017.

"Retail clinics are shifting to a clinical focus with more sophisticated services for consumers who want walk-in convenience for their basic health needs," said Kristin Ficery, managing director of health consulting at Accenture. "This shift provides a release valve for strained health systems, as they prioritize more critical patient cases, and will give consumers another option for addressing their health care needs on their own terms."

However, the report also indicated unease among more-traditional health care providers about the retail clinic model's growth. In a survey of 1,000 physicians, the firm found more than 40 percent of them were comfortable with patients seeking preventive care at the clinics, but fewer than 2 in 5 endorsed using them for either primary care of chronic conditions.

Retail clinic leaders, meanwhile, have made it clear that, ideally, the model will complement traditional care rather than compete with or replace it. "Our role is a safety net. We provide access at low cost and high quality, and get patients to primary care," said Nancy Gagliano, M.D., senior vice president of CVS Caremark and chief medical officer for CVS MinuteClinic, the largest retail clinic provider in the country.

"As more retail clinics shift from cost centers to profit centers, they will be better able to deliver stand-alone profits with greater certainty, so the implications for retailers and health care value chain players will be significant," Ficery said.

Source: FierceHealthcare, November 13, 2015

More Headlines

PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
For Locally Advanced or Metastatic Triple-Negative Type Only